Clinical features | Stents group | Control group | T/Z/χ.2 | P |
---|---|---|---|---|
(n = 26) | (n = 29) | |||
Age (years) | 51.38 ± 8.75 | 51.69 ± 11.64 | 0.109 | 0.914 |
Surgery type (n, %) | Â | Â | 2.988 | 0.224 |
Radical hysterectomy | 0 (0.0%) | 1 (3.4%) | Â | Â |
Radical hysterectomy + pelvic lymphadenectomy | 4 (15.4%) | 9 (31.0%) |  |  |
Radical hysterectomy + pelvic and para-aortic lymphadenectomy | 22 (84.6%) | 19 (65.5%) |  |  |
FIGO clinical stage (n, %) | Â | Â | 0.906 | 0.636 |
Stage I | 14 (53.8) | 18 (62.1) | Â | Â |
Stage II | 7 (26.9) | 8 (27.6) | Â | Â |
Stage III | 5 (19.2) | 3 (10.3) | Â | Â |
Pathological type (n, %) | Â | Â | 1.257 | 0.533 |
Carcinoma, squamous cell | 23 (88.5) | 25 (86.2) | Â | Â |
Adenocarcinoma | 2 (7.7) | 1 (3.4) | Â | Â |
Carcinoma, denosquamous | 1 (3.8) | 3 (10.3) | Â | Â |
Radiotherapy time (days) | 38.50 ± 7.49 | 35.48 ± 5.08 | 1.765 | 0.083 |
Creatinine (µmol L−1) | 62.18 ± 6.45 | 58.28 ± 7.88 | 1.995 | 0.051 |
Urea nitrogen (mmol L−1) | 4.00 ± 1.13 | 4.10 ± 1.05 | 0.342 | 0.734 |
Glomerular filtration rate (ml min−1) | 91.13 ± 13.70 | 99.05 ± 15.88 | 1.971 | 0.054 |
Urinalysis specific gravity | 1.01 ± 0.01 | 1.01 ± 0.01 | 0.865 | 0.391 |